Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Coherus Bio (CHRS)
Coherus Bio (CHRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 287,319
  • Shares Outstanding, K 111,364
  • Annual Sales, $ 211,040 K
  • Annual Income, $ -291,750 K
  • 60-Month Beta 0.53
  • Price/Sales 1.05
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CHRS with:

Options Overview Details

View History
  • Implied Volatility 87.22% ( -23.19%)
  • Historical Volatility 89.47%
  • IV Percentile 28%
  • IV Rank 32.39%
  • IV High 254.41% on 02/15/24
  • IV Low 7.12% on 09/01/23
  • Put/Call Vol Ratio 0.02
  • Today's Volume 147
  • Volume Avg (30-Day) 585
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 17,699
  • Open Int (30-Day) 23,133

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.33
  • Number of Estimates 3
  • High Estimate -0.25
  • Low Estimate -0.38
  • Prior Year -0.76
  • Growth Rate Est. (year over year) +56.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.92 +34.03%
on 02/05/24
2.87 -10.10%
on 02/15/24
+0.18 (+7.50%)
since 01/23/24
3-Month
1.84 +40.22%
on 11/28/23
3.70 -30.27%
on 01/02/24
+0.56 (+27.72%)
since 11/22/23
52-Week
1.43 +80.41%
on 11/10/23
8.65 -70.17%
on 04/17/23
-4.65 (-64.32%)
since 02/23/23

Most Recent Stories

More News
Why Coherus BioSciences Stock Jumped Today

As promised, Coherus is using the proceeds of a recent divestiture to pay down debt and reduce interest expenses.

CHRS : 2.58 (+4.45%)
Why Coherus BioSciences Stock Is Sinking Today

The positive reaction to Coherus' sale of its ophthalmology franchise to Sandoz didn't last long.

CHRS : 2.58 (+4.45%)
Why Coherus Biosciences Popped Today

Coherus is divesting its non-core ophthalmology franchise.

SDZNY : 31.8000 (-0.53%)
CHRS : 2.58 (+4.45%)
Why Coherus BioSciences Stock Jumped Today

Coherus finally received FDA approval for its Udenyca OnBody injector system.

CHRS : 2.58 (+4.45%)
Cytokinetics, New York Times rise; Iovance Biotherapeutics fall, Wednesday, 12/27/2023

Stocks that are trading heavily or have substantial price changes on Wednesday: Cytokinetics, New York Times rise; Iovance Biotherapeutics fall

CYTK : 78.02 (+3.21%)
NEM : 31.28 (+1.26%)
TMUS : 164.34 (+0.48%)
FCX : 38.96 (+0.75%)
TM : 235.00 (+0.23%)
CHRS : 2.58 (+4.45%)
NYT : 43.55 (+0.86%)
2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street

These two biotech stocks could be poised for a trend reversal.

BMY : 51.66 (+0.64%)
AGEN : 0.6821 (+1.05%)
CHRS : 2.58 (+4.45%)
Why Coherus BioSciences Was Plummeting This Week

The company has been punished harshly for a worse-than-expected quarter.

TFC : 35.24 (-1.12%)
CHRS : 2.58 (+4.45%)
Why Coherus Biosciences Stock Dropped Today

Coherus missed estimates for the third quarter and lowered its full-year outlook.

CHRS : 2.58 (+4.45%)
Coherus BioSciences: Q3 Earnings Snapshot

Coherus BioSciences: Q3 Earnings Snapshot

CHRS : 2.58 (+4.45%)
Why Coherus BioSciences Stock Soared Today

Coherus and Junshi Biosciences announced the long-awaited FDA approval of NPC drug Loqtorzi. Here's what investors need to know.

CHRS : 2.58 (+4.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid...

See More

Key Turning Points

3rd Resistance Point 2.83
2nd Resistance Point 2.71
1st Resistance Point 2.65
Last Price 2.58
1st Support Level 2.47
2nd Support Level 2.35
3rd Support Level 2.29

See More

52-Week High 8.65
Fibonacci 61.8% 5.89
Fibonacci 50% 5.04
Fibonacci 38.2% 4.19
Last Price 2.58
52-Week Low 1.43

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar